BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 24795040)

  • 1. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
    Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
    Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
    Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
    Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus.
    Shah SL; Dunbar K
    Curr Gastroenterol Rep; 2023 Dec; 25(12):374-379. PubMed ID: 37940812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
    Hur C; Nishioka NS; Gazelle GS
    J Natl Cancer Inst; 2004 Feb; 96(4):316-25. PubMed ID: 14970280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
    Yao H; Wang L; Li H; Xu S; Bai Z; Wu Y; Chen H; Goyal H; Qi X
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):79-88. PubMed ID: 34806503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Acid Suppression in Barrett's Esophagus.
    Elias PS; Castell DO
    Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
    Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
    Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
    Tan MC; El-Serag HB; Yu X; Thrift AP
    Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical decision analysis of chemoprevention against esophageal adenocarcinoma.
    Sonnenberg A; Fennerty MB
    Gastroenterology; 2003 Jun; 124(7):1758-66. PubMed ID: 12806608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Status of Chemoprevention in Barrett's Esophagus.
    Moayyedi P; El-Serag HB
    Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
    Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
    Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
    Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's esophagus: proton pump inhibitors and chemoprevention II.
    Richter JE; Penagini R; Tenca A; Pohl D; Dvorak K; Goldman A; Savarino E; Zentilin P; Savarino V; Watson JT; Wong RK; Pace F; Casini V; Peura DA; Herzig SJ; Kamiya T; Pelosini I; Scarpignato C; Armstrong D; DeVault KR; Bechi P; Taddei A; Freschi G; Ringressi MN; Degli'Innocenti DR; Castiglione F; Masini E; Hunt RH
    Ann N Y Acad Sci; 2011 Sep; 1232():114-39. PubMed ID: 21950810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
    Akın H; Aydın Y
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?
    Spechler SJ
    Dig Dis; 2014; 32(1-2):156-63. PubMed ID: 24603402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis.
    Hu Q; Sun TT; Hong J; Fang JY; Xiong H; Meltzer SJ
    PLoS One; 2017; 12(1):e0169691. PubMed ID: 28072858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.